Valuation: Pulmonx Corporation

Market Cap 82.03M 71.06M 67.19M 60.83M 114M 7.87B 115M 802M 308M 3.99B 308M 301M 12.72B P/E 2026 *
-1.83x
P/E 2027 * -2.03x
Enterprise Value 82.03M 71.06M 67.19M 60.83M 114M 7.87B 115M 802M 308M 3.99B 308M 301M 12.72B EV / Sales 2026 *
0.91x
EV / Sales 2027 * 0.83x
Free-Float
95.36%
Yield 2026 *
-
Yield 2027 * -
1 day-3.05%
1 week-8.17%
Current month-19.75%
1 month-21.07%
3 months+49.22%
6 months+13.69%
Current year-13.57%
1 week 1.82
Extreme 1.815
2
1 month 1.82
Extreme 1.815
2.59
Current year 1.13
Extreme 1.13
2.59
1 year 1.13
Extreme 1.13
2.89
3 years 1.13
Extreme 1.13
14.84
5 years 1.13
Extreme 1.13
45.49
10 years 1.13
Extreme 1.13
69.48
Manager TitleAgeSince
Chief Executive Officer 64 27/10/2025
Director of Finance/CFO 53 01/05/2019
Chief Tech/Sci/R&D Officer - 01/03/2020
Director TitleAgeSince
Director/Board Member 72 01/02/2007
Chairman 66 01/10/2019
Director/Board Member 64 18/12/2014
Date Insider Type Main position Quantity % Market Cap. Importance
1/9/26 Sell

Chief Technology Officer

-14,245 0.0332%
1/9/26 Sell

Chief Executive Officer

-41,882 0.0975%
1/9/26 Sell

Executive/Senior Manager

-7,879 0.0183%
Change 5-day change 1-year change 3-year change Capi.($)
-3.05%-8.17%+20.13%-81.58% 82.03M
-0.45%-0.26%+21.02%+19.00% 12.54B
+0.04%-0.63%+12.36%+18.81% 6.63B
+0.18%-5.62% - - 6.19B
+0.49%+0.25%+23.24%+12.14% 5.56B
-1.23%+2.35%-17.58%+38.98% 5.08B
+2.24%+1.64%-32.72%-24.87% 3.87B
-0.43%-4.15%+26.97%-16.32% 1.88B
0.00%+4.81%-1.29%+187.06% 1.77B
0.00%-1.14%+46.82%-17.70% 1.61B
Average -0.22%-1.85%+10.99%+15.06% 4.52B
Weighted average by Cap. -0.00%-1.45%+9.85%+20.44%

Financials

2026 *2027 *
Net sales 90.55M 78.43M 74.17M 67.14M 126M 8.69B 127M 885M 341M 4.4B 340M 333M 14.05B 98.31M 85.16M 80.53M 72.9M 137M 9.43B 138M 961M 370M 4.78B 369M 361M 15.25B
Net income -44.24M -38.32M -36.23M -32.8M -61.56M -4.24B -62.03M -432M -166M -2.15B -166M -162M -6.86B -40.71M -35.27M -33.35M -30.19M -56.66M -3.91B -57.09M -398M -153M -1.98B -153M -150M -6.32B
Net Debt - -
Logo Pulmonx Corporation
Pulmonx Corporation is a commercial-stage medical technology company. The Company provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.
Employees
296
Date Price Change Volume
15/09/26 USD 1.910 -3.05% 228,930
14/09/26 USD 1.970 +6.49% 292,854
11/09/26 USD 1.850 0.00% 204,925
10/09/26 USD 1.850 -6.57% 479,329
09/09/26 USD 1.980 -4.81% 451,935
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.910USD
Average target price
3.400USD
Spread / Average Target
+78.01%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LUNG Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!